Tirzepatide

Buy Tirzepatide Online

Tirzepatide is a long-acting GIP and GLP-1 receptor agonist developed for metabolic disease. It has extensive clinical evidence in type 2 diabetes and obesity and is marketed in the United States as Mounjaro and Zepbound for different indications.

Product Information

Tirzepatide is a modified peptide engineered for prolonged activity after once-weekly administration. Its dual incretin mechanism combines GIP receptor activation with GLP-1 receptor activation, affecting insulin secretion, glucagon regulation, appetite, and energy balance.

How It Works

Tirzepatide activates both GIP and GLP-1 receptors. These pathways enhance glucose-dependent insulin secretion and influence appetite and energy intake, while the combined signaling produces broad metabolic effects.

POTENTIAL BENEFITS

1. Blood-Glucose Research

Tirzepatide produces substantial reductions in HbA1c in clinical trials involving type 2 diabetes. Its dual incretin activity contributes to improved glucose regulation.

2. Weight-Management Research

Large clinical studies have demonstrated significant body-weight reductions in adults with obesity or overweight. This has made tirzepatide a major subject of modern metabolic research.

3. Insulin-Sensitivity Research

GIP and GLP-1 signaling influence insulin secretion and metabolic regulation. Tirzepatide has therefore been investigated extensively for changes in insulin sensitivity and broader cardiometabolic markers.

4. Metabolic-Disease Research

Tirzepatide research extends beyond glucose and body weight into cardiovascular risk factors, fatty liver disease, sleep apnea, and other obesity-associated conditions.

Dosage

For Zepbound, the current U.S. prescribing information starts at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Further increases can be made in 2.5 mg increments at intervals of at least 4 weeks, with maintenance doses of 5, 10, or 15 mg once weekly depending on indication and tolerability.

Side Effects

The most common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Important warnings include pancreatitis, gallbladder disease, acute kidney injury associated with severe gastrointestinal reactions, and the boxed warning concerning thyroid C-cell tumors observed in rodents.

References

1. FDA — current Zepbound (tirzepatide) prescribing information
2. Tirzepatide and type 2 diabetes — SURPASS clinical research.
3. Tirzepatide and obesity — SURMOUNT clinical research.
4. Tirzepatide cardiovascular and metabolic research.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.